# Are peptides legal in Australia? Research peptide schedule status Peptide legality in Australia depends on the compound, product and activity, including any required prescription, approval or authority. BPC-157, CJC-1295, ipamorelin and TB-500 have named Schedule 4 and Appendix D entries in the October 2026 Poisons Standard (as-made text read 14 October 2026). The TGA says a research-use-only label does not remove regulatory obligations (guidance read 14 October 2026). Research material is not presented here as authorised for personal human use. | | | | --- | --- | | Document read | Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026 | | Register ID | F2026L01327 ([Federal Register of Legislation](https://www.legislation.gov.au/F2026L01327/latest/text)) | | Also cited as | Standard for the Uniform Scheduling of Medicines and Poisons No. 51 (section 1(2)) | | Dated | 28 September 2026 | | In force from | 1 October 2026 (commencement table) | | Replaces | The June 2026 edition, repealed by section 4(1) | | Date read | 14 October 2026, world time (UTC), as-made text on legislation.gov.au | | Catalogue compounds in the table | 12 | | Held, no status stated | GHK-Cu and tesamorelin | | Not covered | Later editions and blended products | | Other regulator pages read | TGA, FDA, Sport Integrity Australia and Australia Post pages, read 14 October 2026 | Read 14 October 2026: the [TGA peptide products page](https://www.tga.gov.au/resources/explore-topic/peptide-products) (last updated 23 September 2026) and [the TGA's explanation of how it regulates therapeutic peptide products](https://www.tga.gov.au/products/medicines/monitoring-and-compliance/how-we-regulate-therapeutic-peptide-products) were read for this update. [Jump to the per-compound schedule table](/learn/peptides-and-australian-law#comparison), which records the October 2026 [Poisons Standard](https://www.legislation.gov.au/F2026L01327/latest/text) (as-made text dated 28 September 2026, in force from 1 October 2026) and the date each entry was read: 14 October 2026. Most readers start with one question: is this peptide legal in Australia? The Poisons Standard classifies substances through named entries and broader group entries. New editions of that list replace old ones, so every statement about it needs a date. This page reads that list against one catalogue. It sets out, compound by compound, what the October 2026 edition says, quotes the entry text and names the day the text was read. It then answers the import and sport questions from the regulators' own pages. It is not legal advice and never says what any person may lawfully do. Western Australia adds a state layer, set out on [the WA law page](/learn/peptides-perth/peptides-and-wa-law). ## Are research peptides legal in Australia? Australian peptide law depends on the substance, product and activity. The TGA regulates peptide products that meet the definition of therapeutic goods under the *Therapeutic Goods Act 1989*. Peptide products regulated as therapeutic goods must be included in the Australian Register of Therapeutic Goods (ARTG) before they can be imported, manufactured, supplied, exported or advertised, and the TGA says some limited exceptions apply, such as a specific approval, authority or exemption under the legislation ([TGA, How we regulate therapeutic peptide products](https://www.tga.gov.au/products/medicines/monitoring-and-compliance/how-we-regulate-therapeutic-peptide-products), read 14 October 2026). State and territory laws may add controls on sale, supply and possession ([TGA advisory](https://www.tga.gov.au/safety/safety-monitoring-and-information/safety-alerts/understanding-your-responsibilities-when-importing-compounding-and-supplying-unapproved-peptide-products), 13 April 2026). The [TGA's April 2026 advisory](https://www.tga.gov.au/safety/safety-monitoring-and-information/safety-alerts/understanding-your-responsibilities-when-importing-compounding-and-supplying-unapproved-peptide-products) defines unapproved peptide products as goods not included in the ARTG. The [TGA's Peptide products page](https://www.tga.gov.au/resources/explore-topic/peptide-products) (last updated 23 September 2026) says how a peptide product is regulated depends on what it contains, how it is promoted and what it is intended to do. The Poisons Standard and the ARTG are separate records: the first lists substances by control level, and the second lists the products the TGA has included (TGA pages read 14 October 2026). The same advisory says unapproved peptide products 'have not been evaluated for safety, quality or effectiveness by the TGA', and that a 'research use only' disclaimer 'does not make its supply lawful' (TGA, 13 April 2026). Those statements are about approval, not scheduling, and the two questions stay apart. The TGA names BPC-157 among its examples of unapproved peptide products, and the October 2026 edition of the Poisons Standard, a legal document called an instrument, gives BPC-157 an individual Schedule 4 entry. The TGA names retatrutide among the same examples, and no individual entry for retatrutide was found in the instrument text read on 14 October 2026. ## Are peptides illegal in Australia, and why? Peptides are not illegal as a class in the regulator's own account. The TGA says some peptide products are approved for use in Australia, while many products promoted online are unapproved therapeutic goods that 'may be unlawful to import, supply or advertise' ([TGA, Peptide products](https://www.tga.gov.au/resources/explore-topic/peptide-products), last updated 23 September 2026). The reason the TGA gives is missing assessment: it has not assessed these products for safety, quality or effectiveness, so there is 'no assurance they are safe, effective, correctly labelled, sterile or made to appropriate quality standards'. Named entries in the Poisons Standard add separate controls. The TGA lists what stays unknown about these products: how they are manufactured, whether they are sterile, how they work in the body, what side effects they may cause and what substances they contain (TGA advisory, 13 April 2026). The advisory lists adverse events and other concerns received by the TGA, including severe allergic reactions requiring adrenaline and hospitalisation, a systemic inflammatory response requiring hospital management, and musculoskeletal injuries including plantar fasciitis and Achilles tendinitis; these are reports to a regulator and not rates (TGA advisory, 13 April 2026). The Chief Medical Officer, Professor Michael Kidd, is quoted in the [joint TGA and Chief Medical Officer statement of 19 June 2026](https://www.tga.gov.au/news/media-releases/concerns-regarding-public-health-risks-associated-unapproved-peptide-products) as saying that 'Some of these products have not undergone sufficient human clinical trials and may cause significant harm.' That is a health warning. The legal rules sit in the Schedule 4, Appendix D, import and possession sections of this page. ## Which peptides are legal in Australia? Peptide medicines with an entry on the ARTG are approved products in Australia. The TGA names insulin and insulin analogues, GLP-1 receptor agonists such as semaglutide, oxytocin, vasopressin analogues such as desmopressin and somatostatin analogues such as octreotide as examples ([TGA, How we regulate therapeutic peptide products](https://www.tga.gov.au/products/medicines/monitoring-and-compliance/how-we-regulate-therapeutic-peptide-products), read 14 October 2026). Tirzepatide, the peptide in Mounjaro, received initial registration in the ARTG on 23 December 2022 ([TGA public assessment report, September 2024](https://tga.gov.au/sites/default/files/2024-09/auspar-mounjaro-240920.pdf)). The TGA says many approved peptide-based medicines are prescription-only. Products not on the ARTG are generally referred to as unapproved therapeutic goods. What peptides are now legal? The sources read on 14 October 2026 did not announce a peptide made newly lawful in 2026. The 2026 changes the sources record are about enforcement. The TGA expanded its priority focus areas to include unapproved peptide products ([TGA media release](https://www.tga.gov.au/news/media-releases/tga-strengthens-compliance-focus-unapproved-peptide-products-part-evolving-risk-response), 10 June 2026), and the October 2026 Poisons Standard replaced the June 2026 edition (F2026L01327, section 4(1)). Approval is recorded product by product on the ARTG (TGA, How we regulate therapeutic peptide products). A peptide sold as research material is not the approved medicine, even when the molecule has the same name. The [Peptide Science hub](/learn/peptide-science) sets approved medicines beside unapproved examples. ## Is it legal to sell peptides in Australia? The TGA says unapproved peptide products cannot be imported or supplied in Australia unless a valid exemption, approval or authority applies ([TGA, How we regulate therapeutic peptide products](https://www.tga.gov.au/products/medicines/monitoring-and-compliance/how-we-regulate-therapeutic-peptide-products), read 14 October 2026). The same page states that disclaimers such as 'research use only' or 'not for human use' do not change whether a product is regulated as a therapeutic good, and do not remove advertising, manufacture, import, export or supply obligations. State and territory laws may add controls on sale and supply (TGA advisory, 13 April 2026). Whether a given product counts as a therapeutic good depends on what it contains, how it is promoted and what it is intended to do (TGA, Peptide products, last updated 23 September 2026). This page decides that for no supplier and no product. Enforcement is active. The TGA says that search warrants were executed on 4 August 2026 at 2 residential premises in New South Wales, where it seized more than $120,000 of illicit peptide and anabolic steroid products with the assistance of NSW Police. TGA head Professor Anthony Lawler said that 'selling or supplying online does not place you outside the law' ([TGA media release, 17 August 2026](https://www.tga.gov.au/node/572979)). The release gives penalties for breaches of the *Therapeutic Goods Act 1989* of civil penalties of up to $1.82 million per breach for individuals or $18.2 million per breach for corporations, and criminal penalties of up to 7 years imprisonment (TGA, 17 August 2026). In a [media release of 20 July 2026](https://www.tga.gov.au/news/media-releases/unapproved-peptide-product-promoters-and-suppliers-are-put-notice), Professor Lawler said he had written directly to social media and e-commerce platforms about unlawful advertising and sale of unapproved peptide products. Is it illegal to shop for peptides? The TGA says people and businesses that import, supply, manufacture, export, advertise, prescribe or compound peptide products must understand and comply with their legal obligations (TGA, Peptide products). That sentence does not list buying, so this page reads a buyer's position through the import and possession rules in the sections around it and states no verdict. [The WA law page](/learn/peptides-perth/peptides-and-wa-law) covers the state layer. ## What can this page not tell you? This page records one dated reading of one document, and the reading gives no verdict on any person's situation. The Federal Register of Legislation supplied F2026L01327, the October 2026 Poisons Standard, dated 28 September 2026; the as-made text was read on 14 October 2026, in world time (UTC). A later edition may differ, and this page does not cover one. GHK-Cu and tesamorelin are held, so the page states no status for either. Blended products are not covered. An instrument is the legal document that holds the list, and an edition is one dated version of it. The instrument's own reader's guide says inclusion of a poison in a Schedule indicates the degree of control required if it is marketed, and does not indicate that the poison is available or approved, or negate any obligation for registration of therapeutic goods. So a Schedule entry is a classification, not a permission, and a missing entry is not a permission either. Section 7 of the instrument says that, unless the contrary intention appears, a reference to a substance includes 'every salt, active principle or derivative of the substance' and 'a preparation or admixture containing any proportion of the substance'. A derivative is a substance made by changing the original. A named entry can therefore reach more than the exact name, and a missing name does not settle what the group headings (class entries) cover. New editions replace old ones: section 4(1) of the October 2026 instrument repeals the June 2026 edition. This page is meant to be re-read against each new edition, and the read date in the table shows which edition was last checked. ## Which research peptides are in Schedule 4? Schedule 4, headed 'Prescription only medicines and prescription animal remedies', holds BPC-157, CJC-1295 (named with CAS No. 863288-34-0), ipamorelin, TB-500 and tirzepatide as named entries in [F2026L01327](https://www.legislation.gov.au/F2026L01327/latest/text), the October 2026 instrument (as-made text read 14 October 2026, UTC). A CAS number is a registry number that identifies one chemical. The first four entries carry a # marker, which the instrument's note explains as 'Substances marked # are listed in Appendix D', and also appear in Appendix D; tirzepatide's does not. For the other seven catalogue compounds, no Schedule 4 status is stated here: five have no individual entry found and two are held. The table below quotes each entry text, with the instrument's spaced hyphens written as ordinary hyphens. The research guides set each compound in context: [BPC-157](/research/bpc-157), [CJC-1295 with ipamorelin](/research/cjc-1295-ipamorelin) and [TB-500](/research/tb-500). This site's catalogue lists a product named 'CJC-1295 (No DAC) & Ipamorelin'. The instrument names CJC-1295 with the CAS number above and does not use the label 'No DAC', so this page does not decide whether that form falls under the named entry. ## What is Appendix D in the Poisons Standard? Appendix D, clause 5 (a numbered part of the appendix), headed 'Poisons for which possession without authority is illegal', is a table in the Poisons Standard that, in the instrument's words, 'specifies poisons that must not be possessed by a person without authority (for example, possession other than in accordance with a legal prescription)'. An appendix is a table or list placed after the schedules in the instrument. The 14 October 2026 (UTC) reading of the as-made text of F2026L01327, the October edition, places BPC-157 at item 5, CJC-1295 at item 7, ipamorelin at item 25 and TB-500 at item 38 of the clause 5 table, which has 41 items. Item numbers can change between editions while an entry stays, which is why the table names the item and the edition together. State and territory laws may add controls on possession (TGA advisory, 13 April 2026), so the instrument alone does not settle any person's position, and this page does not try to. Tirzepatide follows a different path. Its Schedule 4 entry has no # marker, so it has no Appendix D entry, and it appears in Appendix L, clause 2 ('Additional warning statements for certain human medicines'), item 41, which points to warning statement number 67 in Appendix F, clause 1. The warning text is not reproduced here. ## Is it illegal to possess peptides in Australia? Possession is controlled by substance, not by the word 'peptide'. Section 64(4) of the October 2026 Poisons Standard says a poison included in the table in clause 5 of Appendix D 'must not be possessed by a person without authority under the law of the jurisdiction in which the possession occurs' ([F2026L01327](https://www.legislation.gov.au/F2026L01327/latest/text), as-made text read 14 October 2026). That table names BPC-157, CJC-1295, ipamorelin, TB-500 and AOD-9604 among its 41 items. For other peptides, state and territory laws may add controls on possession (TGA advisory, 13 April 2026). The clause 5 table also holds group entries. Its items 15, 16, 18, 19, 21 and 24 name fibroblast growth factors, follistatin, growth hormone releasing hormones, growth hormone releasing peptides, growth hormone secretagogues and insulin-like growth factors, and item 39 names thymosin beta 4. Items 18, 19 and 21 add 'including those separately specified in Schedule 4' (read 14 October 2026). 'Authority' is the instrument's own word, and its example is a legal prescription (Appendix D, clause 5). Whether a person may lawfully use a peptide is not answered for any person by a regulator page read, and this page does not answer it. The [19 June 2026 joint statement from the TGA and the Chief Medical Officer](https://www.tga.gov.au/news/media-releases/concerns-regarding-public-health-risks-associated-unapproved-peptide-products) is a health warning about unapproved peptide products, not a legal ruling. ## What does 'no individual entry' mean? 'No individual entry' means the text search of the as-made October instrument F2026L01327 on 14 October 2026 (UTC) found no named entry. The search covered semax, selank, NAD+, MOTS-c and retatrutide, using each name plus variant spellings, spelled-out names and research codes (lab identifiers) where they exist. The result is not a statement that any of them is lawful, approved, free to possess or free to sell. It also does not show that no group heading applies, because section 7 reaches derivatives and preparations. Scheduling status and TGA approval are separate questions. NAD+ is short for nicotinamide adenine dinucleotide. It is a coenzyme, a helper molecule for enzymes (Covarrubias et al., 2021, a review article). NAD+ has a nucleotide structure, made of small chemical building blocks rather than an amino-acid chain ([ChEBI, CHEBI:15846](https://www.ebi.ac.uk/chebi/CHEBI:15846)). The instrument text read has no entry under either name. ## Can you import peptides into Australia? The TGA says a 'research use only' disclaimer does not permit importation ([TGA advisory](https://www.tga.gov.au/safety/safety-monitoring-and-information/safety-alerts/understanding-your-responsibilities-when-importing-compounding-and-supplying-unapproved-peptide-products), 13 April 2026). Under the [Personal Importation Scheme](https://www.tga.gov.au/products/unapproved-therapeutic-goods/access-pathways/personal-importation-scheme), the TGA scheme for people importing goods for themselves or immediate family, an import is covered only if all of the scheme's conditions are met (TGA, last updated 8 September 2026, read 14 October 2026). The conditions include a valid Australian prescription or written authority when the medicine is prescription-only in Australia, and original packaging or packaging that allows the product to be accurately identified (TGA, Personal Importation Scheme, last updated 8 September 2026). The [TGA warning of 7 May 2026](https://www.tga.gov.au/safety/safety-monitoring-and-information/safety-alerts/tga-warning-risks-importing-unapproved-peptide-products) says poorly labelled vials will not be released under the scheme. The scheme covers goods for the importer's own or immediate family's use, and they 'cannot be sold or supplied to any other person' (TGA, Personal Importation Scheme). The TGA says that where peptide products do not meet the requirements because of poor labelling, it will notify Australian Border Force (ABF) to seize and destroy them at the border (TGA, 7 May 2026). No compound is tested against those conditions here. A parcel posted between two Australian addresses is not an import; [the Perth ordering page](/learn/peptides-perth/why-order-peptides-from-perth-instead-of-importing) covers that side, and state and territory laws may still add controls. These conditions are recorded here as regulatory facts, without assessing any proposed personal import. ## Is it illegal to mail peptides, or to bring them into Australia? Australia Post's [Prohibited and Restricted Items List and Packaging Guide](https://auspost.com.au/content/dam/auspost_corp/media/documents/prohibited-and-restricted-items-list.pdf) (22 May 2024 edition, read 14 October 2026) lists among toxic substances 'any poison listed in the Commonwealth Standard for Uniform Scheduling of Drugs & Poisons', which this page takes to mean the Poisons Standard, except therapeutic drugs and medicines, ready for use, carried under the conditions in its Restricted Items List, which include that carriage will not cause a breach of any State, Territory or Commonwealth law. For goods coming from overseas, the TGA says a 'research use only' disclaimer does not permit importation, and goods that fail the Personal Importation Scheme conditions may be seized and destroyed (TGA advisory, 13 April 2026; TGA warning, 7 May 2026). For a scheduled medicine sent under those conditions, the guide's domestic rules also say the item must be prescribed for therapeutic purposes by a qualified medical practitioner, dentist, pharmacist or veterinarian, and the addressee must be such a practitioner, a hospital or medical clinic, or the person for whom the substance was prescribed. The guide names no peptides. Whether a given peptide is a scheduled poison depends on the Poisons Standard entries read in the sections above. People bringing goods in by hand have a separate route. The TGA's [Entering Australia page](https://www.tga.gov.au/resources/consumer-information-and-resources/travelling-medicines-and-medical-devices/entering-australia) (last updated 27 March 2024, read 14 October 2026) describes the traveller's exemption for certain medicines for personal use or for an immediate family member travelling with the person. It asks for the product to be kept in its original packaging, for prescription medicines a prescription or doctor's letter, and no more than a 3-month supply. Its list of covered categories includes medicines that lower blood glucose and does not name research peptides. The import section above links to the TGA's full Personal Importation Scheme requirements. ## Are peptides banned in sport in Australia? Many peptides are prohibited in sport under the World Anti-Doping Code, the international anti-doping rulebook, according to Sport Integrity Australia (SIA) in its [statement of 13 May 2026](https://www.sportintegrity.gov.au/news/media-statements/2026-05/sport-integrity-australia-warns-athletes-peptides-pose-serious-anti-doping-and-health-risks). SIA lists BPC-157, CJC-1295, ibutamoren (MK-677), ipamorelin, MOTS-c and thymosin beta-4 (TB-500) among common examples ([SIA, Peptides explained](https://www.sportintegrity.gov.au/what-we-do/anti-doping/substance-education/peptides), page read 14 October 2026). Under Australia's strict-liability rules, athletes are accountable for any prohibited substance in their system, no matter the source (SIA, 13 May 2026). These are sport rules, separate from the Poisons Standard. A Therapeutic Use Exemption (TUE) is an approval that can let an athlete use a prohibited medicine that a doctor prescribes. SIA says a TUE is 'unlikely to be granted for an unregistered medicine', and that the athlete may then be subject to an anti-doping rule violation (ADRV) (SIA, Peptides explained). SIA points athletes to the Global DRO website, which shows the status of substances on the World Anti-Doping Agency (WADA) Prohibited List, and to the Sport Integrity App. No sport statement is made here about any compound that those SIA pages do not name. ## What peptides has the FDA banned? The FDA pages read publish no ban on peptides as a class. Its compounding rules sort certain bulk drug substances into categories, and category 2 lists substances that may present significant safety risks ([FDA, page current as of 22 April 2026](https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks), read 14 October 2026). That list names the peptides GHRP-2, GHRP-6, ipamorelin acetate and kisspeptin-10. BPC-157, CJC-1295, TB-500 and 14 other substances sit on a separate list on the same page, of substances nominated but withdrawn by the nominators. These lists concern compounding, which is separate from FDA approval of a drug. The FDA's wording concerns compounding, where a pharmacy prepares a medicine for one patient. Under section 503A, state-licensed pharmacists and physicians may compound only with bulk substances that meet a pharmacopoeia monograph, are components of FDA-approved drugs, or appear on the 503A bulks list. For category 2 substances the FDA says it 'would consider taking action against a compounder' under its general enforcement policies ([FDA, 503A bulk drug substances page](https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act), content current as of 14 May 2026, read 14 October 2026). The agenda of the FDA's [23 and 24 July 2026 Pharmacy Compounding Advisory Committee meeting page](https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026) (content current as of 6 August 2026, read 14 October 2026) lists seven substances considered for inclusion on the 503A bulks list: BPC-157, KPV, TB-500, MOTs-C, emideltide, semax and epitalon. The FDA states that advisory committees make non-binding recommendations, and the meeting page read carries no vote result, so this page reports none. Enforcement against sellers is a separate track. An [FDA warning letter of 24 August 2026](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/nuscience-peptides-llc-733652-08242026) (letter 733652) says that, despite labelling statements marketing the products 'for laboratory, research, and analytical use' and 'not intended for human or veterinary use', evidence from the seller's website establishes that the products are intended to be drugs for human use. It names nine products, including ones labelled 'GLP-1 Sema Research Peptide', 'GLP-2 Tirz Peptide', 'GLP-3 RT (Retatrutide) Research Peptide' and 'Tesamorelin Research Peptide', as unapproved new drugs (FDA, 24 August 2026). [Retatrutide's status in Australia and the US](/learn/retatrutide/is-retatrutide-legal-in-australia) records the retatrutide detail. ## Are peptides legal in Perth? Perth sits under two layers of law: Commonwealth therapeutic-goods rules and Western Australian medicines and poisons law. The TGA states that state and territory laws may add controls on the sale, supply and possession of unapproved peptide products (TGA advisory, 13 April 2026). Western Australia gives the Poisons Standard schedules effect through regulation 6 of the [Medicines and Poisons Regulations 2016](https://www.legislation.wa.gov.au/legislation/statutes.nsf/law_s48030.html), which classifies each substance described in its Table, other than an exempt substance or nicotine, as a poison included in the Schedule specified in that item (version 00-u0-00, in force from 2 October 2026, read 14 October 2026). The answer for any one peptide still depends on the substance and the activity. The WA page also covers the Research/Education permit, which the Regulations describe as a permit 'to use specified poisons for the purpose of education or research on behalf of a specified school, university, government department or research organisation'. This page does not repeat that record. ## Comparison Twelve catalogue compounds compared against F2026L01327, the October 2026 Poisons Standard. Source reading: as-made text, 14 October 2026 (UTC). A class entry is a group heading that can cover more than one substance. GHK-Cu and tesamorelin are held: this page states no status for them. Later editions are not covered. | Compound | Entry text in the instrument | Schedule and appendix | Class-entry caution | Date read | | --- | --- | --- | --- | --- | | BPC-157: a 15-amino-acid fragment of a peptide from gastric (stomach) juice (Sikirić et al., 1993) | '# BPC-157.' | Schedule 4; Appendix D, clause 5, item 5 | Named entry. Section 7 reaches derivatives and preparations. | 14 October 2026 | | CJC-1295: a lab-made analogue (modified copy) of growth-hormone-releasing hormone (Teichman et al., 2006) | '# CJC-1295 (CAS No. 863288-34-0).' | Schedule 4; Appendix D, clause 5, item 7 | Named entry with a CAS number. The instrument does not use the catalogue label 'No DAC'. | 14 October 2026 | | Ipamorelin: a lab-made peptide five amino acids long (Raun et al., 1998) | '# IPAMORELIN.' | Schedule 4; Appendix D, clause 5, item 25 | Named entry; section 7 applies as above. | 14 October 2026 | | TB-500: a peptide product ingredient named by the TGA (13 April 2026) | '# TB-500.' | Schedule 4; Appendix D, clause 5, item 38 | Named entry, separate from the entry for thymosin beta 4. | 14 October 2026 | | Tirzepatide: a lab-made peptide with a fatty acid attached (Coskun et al., 2018; Hammoud et al., 2024) | 'TIRZEPATIDE.' | Schedule 4; Appendix L, clause 2, item 41 (warning statement number 67) | Named entry with no # marker, so no Appendix D entry. | 14 October 2026 | | Semax: a seven-amino-acid peptide modelled on a fragment of the hormone ACTH (adrenocorticotropin, a body signal) (Dolotov et al., 2006) | None found under the name 'semax'. | No individual entry found | Not a statement that it is lawful or outside every group heading. | 14 October 2026 | | Selank: a synthetic (lab-made) analogue (modified copy) of the peptide tuftsin (Kolomin et al., 2011) | None found under the name 'selank' or its variants. | No individual entry found | No group-heading conclusion is drawn for selank. | 14 October 2026 | | NAD+: nicotinamide adenine dinucleotide, a coenzyme (a helper molecule for enzymes), not a peptide (Covarrubias et al., 2021, a review article; [ChEBI, CHEBI:15846](https://www.ebi.ac.uk/chebi/CHEBI:15846)) | None found under either name. | No individual entry found | Whether any group heading covers NAD+ is not decided here. | 14 October 2026 | | MOTS-c: a 16-amino-acid peptide encoded in mitochondrial DNA, the genetic instructions inside the energy-making parts of cells (Lee et al., 2015) | None found under the name 'MOTS-c' or its variants. | No individual entry found | Whether a group heading reaches MOTS-c is left open here. | 14 October 2026 | | Retatrutide: a lab-made peptide (Jastreboff et al., 2023) | None found under the name or research codes. | No individual entry found | No conclusion is drawn on group headings for retatrutide. | 14 October 2026 | | GHK-Cu: the copper form of a peptide called GHK (catalogue record of this site) | HELD. No entry text is quoted. | HELD. No status is stated. | HELD. This page states no status for GHK-Cu, in either direction. | Held | | Tesamorelin: a peptide (catalogue record of this site) | HELD. No entry text is quoted. | HELD. No status is stated. | HELD. This page states no status for tesamorelin, in either direction. | Held | ## Frequently asked questions ### Is BPC-157 legal in Australia? The October 2026 Poisons Standard, as-made text read on 14 October 2026, lists BPC-157 by name in Schedule 4 and at item 5 of Appendix D, clause 5. Those are classifications, not a verdict on any person's situation. In its 13 April 2026 advisory, the TGA lists BPC-157 as one example of an unapproved peptide product. [The BPC-157 research guide](/research/bpc-157) covers the compound itself. ### Is CJC-1295 Schedule 4 in Australia? CJC-1295 has an individual Schedule 4 entry, written '# CJC-1295 (CAS No. 863288-34-0).', and an Appendix D, clause 5 entry at item 7, in the October 2026 instrument, as-made text read on 14 October 2026. The entry names one CAS number. Whether a given formulation falls under it is not decided on this page. ### Are ipamorelin and TB-500 Schedule 4 in Australia? Both have individual entries in F2026L01327, the October 2026 edition, as-made text read on 14 October 2026: '# IPAMORELIN.' with Appendix D item 25, and '# TB-500.' with Appendix D item 38. Thymosin beta 4 has its own separate entries. Each entry is a classification and decides nothing about any person's situation. ### Does 'research use only' make peptides legal in Australia? No. The TGA states that a 'research use only' disclaimer does not make a product's supply lawful, and that such disclaimers do not change a product's regulatory status, permit importation or remove advertising or supply obligations (TGA advisory, 13 April 2026). ### Is NAD+ a peptide? No. NAD+ is nicotinamide adenine dinucleotide, a coenzyme with a nucleotide structure, not a chain of amino acids (Covarrubias et al., 2021, a review article; [ChEBI, CHEBI:15846](https://www.ebi.ac.uk/chebi/CHEBI:15846)). The 14 October 2026 text search of the October 2026 instrument found no individual entry for it, and that finding is not a statement that it is lawful. ### Are peptides legal in Australia? It depends on the substance, the product and the activity. The [TGA](https://www.tga.gov.au/resources/explore-topic/peptide-products) says some peptide products are approved, and that many products promoted online are unapproved therapeutic goods that may be unlawful to import, supply or advertise (last updated 23 September 2026). Named peptides also carry Poisons Standard entries. ### Can I legally import peptides into Australia? The TGA says a 'research use only' disclaimer does not permit importation. Unapproved products can enter under the Personal Importation Scheme only if every condition is met, and poorly labelled vials will not be released (TGA, 13 April and 7 May 2026). The import section above summarises selected conditions and links to the TGA's full requirements. ### Is it illegal to mail peptides? Australia Post's guide lists poisons in the Commonwealth Standard for Uniform Scheduling of Drugs & Poisons among prohibited toxic substances, except therapeutic drugs and medicines, ready for use, carried under its Restricted Items List conditions, which include not causing a breach of any State, Territory or Commonwealth law (22 May 2024 edition, read 14 October 2026). The guide does not name peptides. ### What peptides did the FDA ban? The FDA pages read publish no class ban. Its category 2 compounding list, current as of 22 April 2026, names GHRP-2, GHRP-6, ipamorelin acetate and kisspeptin-10 among peptides that may present significant safety risks. ### Are peptides legal in Perth? Perth follows Commonwealth rules plus Western Australia's Medicines and Poisons Regulations 2016, regulation 6 of which classifies substances listed in the current Poisons Standard schedules as poisons in the matching WA Schedule (version 00-u0-00, read 14 October 2026). The answer still depends on the peptide and the activity. ## Citations - Sikirić P et al.. Journal of Physiology-Paris. 1993;87(5):313-327. DOI: 10.1016/0928-4257(93)90038-U - Teichman SL et al.. Journal of Clinical Endocrinology & Metabolism. 2006;91(3):799-805. DOI: 10.1210/jc.2005-1536 - Raun K et al.. European Journal of Endocrinology. 1998;139(5):552-561. DOI: 10.1530/eje.0.1390552 - Coskun T et al.. Molecular Metabolism. 2018;18:3-14. DOI: 10.1016/j.molmet.2018.09.009 - Dolotov OV et al.. Brain Research. 2006;1117(1):54-60. DOI: 10.1016/j.brainres.2006.07.108 - Kolomin T et al.. Regulatory Peptides. 2011;170(1-3):18-23. DOI: 10.1016/j.regpep.2011.05.001 - Covarrubias AJ et al.. Nature Reviews Molecular Cell Biology. 2021;22(2):119-141. DOI: 10.1038/s41580-020-00313-x - Lee C et al.. Cell Metabolism. 2015;21(3):443-454. DOI: 10.1016/j.cmet.2015.02.009 - Jastreboff AM et al.. New England Journal of Medicine. 2023;389(6):514-526. DOI: 10.1056/NEJMoa2301972 - Hammoud R et al.. JCI Insight. 2024 Dec 26;10(3):e174825. DOI: 10.1172/jci.insight.174825 [Research compound catalogue](/shop) [More on Western Australian law](/learn/peptides-perth/peptides-and-wa-law) ## Articles in this hub - [What did the March 2026 PBAC decide on tirzepatide?](https://www.formlaboratories.com/learn/peptides-and-australian-law/tirzepatide-pbac-march-2026-status) - The March 2026 PBAC recommendation for tirzepatide, with the dated official decision linked. A committee recommendation does not establish a listing date. - [What did the November 2025 PBAC decide on semaglutide?](https://www.formlaboratories.com/learn/peptides-and-australian-law/semaglutide-pbac-november-2025-status) - The November 2025 PBAC semaglutide recommendation for a defined cardiovascular disease and obesity population, linked to the official decision and its date. - [What is the status of the retatrutide TRIUMPH-OUTCOMES trial?](https://www.formlaboratories.com/learn/peptides-and-australian-law/retatrutide-triumph-outcomes-status) - NCT06383390: the dated ClinicalTrials.gov status of retatrutide TRIUMPH-OUTCOMES, its estimated completion and whether registry results are posted. - [What Schedule 4 and Appendix D mean for research peptides](https://www.formlaboratories.com/learn/peptides-and-australian-law/what-schedule-4-and-appendix-d-mean) - What Schedule 4 and Appendix D, clause 5 of the October 2026 Poisons Standard mean, set side by side with the exact clause wording, read 1 October 2026. --- Canonical page: https://www.formlaboratories.com/learn/peptides-and-australian-law Form Laboratories - Perth-based research-use-only peptide supplier, shipping Australia-wide. - Site guide for agents: https://www.formlaboratories.com/llms.txt - Sitemap: https://www.formlaboratories.com/sitemap.xml - Full catalogue: https://www.formlaboratories.com/shop - Contact: hello@formlaboratories.com All materials are supplied for laboratory research use only - not for human or veterinary use, and nothing on this site is medical advice.